Today, we announced our strategic collaboration with Bayer | Pharmaceuticals for development of novel targeted radionuclide therapies in #oncology. Full press release: https://bit.ly/3MfiNpy. Thank you to our internal BD and legal teams for the exceptional work on this deal!

We’re pleased to announce the appointment of Santiago Arroyo, M.D., Ph.D., as Chief Development Officer at Bicycle. Dr. Arroyo brings over 20 years of biopharmaceutical industry experience leading clinical development across multiple disease areas. Learn more: https://bit.ly/3MbqM7a

Today, we announced Phase I dose escalation results from our ongoing Phase I/II study of BT8009, a novel BTC™ targeting Nectin-4 being presented at #GU23. Full press release: http://bit.ly/3xlrQwN

This year at #SITC2022, our team is presenting five posters highlighting preclinical data from our Bicycle tumor-targeted immune cell agonist™ (Bicycle TICA) programs. Full press release: https://bit.ly/3EkQKki

Check out this job at Bicycle Therapeutics: Director, DMPK. A great opportunity to advance our understanding of this new class of molecules!

Really excited about the Nobel prize in chemistry today. I am sure like many of you bioorthogonal (click) chemistry has changed the way we develop reagents, do chemistry and biology and even how we discover and optimize Bicycles as potential drug candidates. Combine that with SPPS and phage display, and we here at #BicycleTx are chock full of Nobel prize winning techniques. We have an opening in the med chem group, so if you also really like this stuff, check it out!

Another great opportunity at Bicycle Therapeutics, leading our #DMPK team! If interested, apply below or message me for more details. #oneteam #oncology #nowhiring #biotechjobs